A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein called an estrogen receptor to make them sensitive to hormone therapy. Saranya Chumsri, MD, an oncologist at the Greenebaum Cancer Center and assistant professor of medicine at the University of Maryland School of Medicine, is the principal investigator of the newly opened National Cancer Institute-funded study. The trial is based on laboratory studies by Angela H. Brodie, Ph.D., an internationally recognized University of Maryland breast cancer researcher, and her colleagues. Related Links: News Release: Clinical Trial Tests New Approach to Treat Triple-Negative Breast Cancer www.umgcc.org Hormone Responsive Cancer Research Program www.umgcc.org University of Maryland Greenebaum Cancer Center www.umgcc.org Breast Evaluation and Treatment Program www.umgcc.org Video: Triple-Negative Breast Cancer www.umm.edu Patient Education www.umgcc.org
Read this article: Clinical Trial for Triple-Negative Breast Cancer
strauss kahn colbert super pac colbert super pac nortel nortel volt volt
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.